? FUNCTIONAL GENOMICS SHARED RESOURCE The Functional Genomics (FG) shared resource was a developing shared resource and is being submitted as a new Duke Cancer Institute (DCI) ? CCSG Shared Resource. Functional Genomics supports Duke Cancer Institute investigators by providing a broad range of services to facilitate the application of functional genomics technologies, including CRISPR/Cas9, RNAi- and ORF-based approaches. Through investments in genetic and chemical perturbagen collections and high-throughput screening infrastructure, we have assembled state-of-the-art technological platforms for functional studies in both high-and low-throughput applications. The FG provides expertise and assistance in developing and implementing genetic screens in arrayed or pooled format, as well as custom services for the creation of individual knock-out, knock- in or overexpression experimental models. In addition, FG enables screening of diverse compound collections with either cell-based or biochemical assays for chemical genetic or drug discovery studies. FG also provides access to advanced instrumentation for screen-related or standalone assays, including multimodal plate readers and a high-content screening (HCS) system for image-based analysis. Finally, the FG is dedicated to developing and adapting new functional genomic techniques and reagents to better support the needs of DCI investigators, enabling them to keep pace with the rapidly evolving field of functional genomics. In 2018, Functional Genomics provided services to 60 investigators, 58% of whom were DCI members who accounted for 66% of total usage and represented 7 of the 8 DCI Research Programs. Use of the shared resource by DCI members contributed to 24 publications over the current project period, 11 of which were in high impact journals (Impact Factor>9), demonstrating the value of services offered by this new resource.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA014236-46
Application #
9853593
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-01-01
Budget End
2020-12-31
Support Year
46
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Duke University
Department
Type
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Xu, Yinghui; Wang, Yanru; Liu, Hongliang et al. (2018) Genetic variants in the metzincin metallopeptidase family genes predict melanoma survival. Mol Carcinog 57:22-31
Abdi, Khadar; Kuo, Chay T (2018) Laminating the mammalian cortex during development: cell polarity protein function and Hippo signaling. Genes Dev 32:740-741
Lu, Min; Sanderson, Sydney M; Zessin, Amelia et al. (2018) Exercise inhibits tumor growth and central carbon metabolism in patient-derived xenograft models of colorectal cancer. Cancer Metab 6:14
Qian, Danwen; Liu, Hongliang; Wang, Xiaomeng et al. (2018) Potentially functional genetic variants in the complement-related immunity gene-set are associated with non-small cell lung cancer survival. Int J Cancer :
Ashcraft, Kathleen A; Choudhury, Kingshuk Roy; Birer, Sam R et al. (2018) Application of a Novel Murine Ear Vein Model to Evaluate the Effects of a Vascular Radioprotectant on Radiation-Induced Vascular Permeability and Leukocyte Adhesion. Radiat Res 190:12-21
Ong, Cecilia T; Campbell, Brittany M; Thomas, Samantha M et al. (2018) Metaplastic Breast Cancer Treatment and Outcomes in 2500 Patients: A Retrospective Analysis of a National Oncology Database. Ann Surg Oncol 25:2249-2260
Duan, Bensong; Hu, Jiangfeng; Liu, Hongliang et al. (2018) Genetic variants in the platelet-derived growth factor subunit B gene associated with pancreatic cancer risk. Int J Cancer 142:1322-1331
Wu, Mengxi; Huang, Po-Hsun; Zhang, Rui et al. (2018) Circulating Tumor Cell Phenotyping via High-Throughput Acoustic Separation. Small 14:e1801131
Vlahovic, Gordana; Meadows, Kellen L; Hatch, Ace J et al. (2018) A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer. Oncologist 23:782-790
Xu, Yinghui; Liu, Hongliang; Liu, Shun et al. (2018) Genetic variant of IRAK2 in the toll-like receptor signaling pathway and survival of non-small cell lung cancer. Int J Cancer 143:2400-2408

Showing the most recent 10 out of 513 publications